<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8128">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774604</url>
  </required_header>
  <id_info>
    <org_study_id>CPHS#23749</org_study_id>
    <nct_id>NCT01774604</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin to Prevent Post-ERCP Pancreatitis</brief_title>
  <official_title>Rectal Indomethacin to Prevent Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether peri-procedural administration of rectal
      indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Rate of post-ERCP pancreatitis in all patients</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess whether rectal indomethacin, compared to placebo, will lower the rate of post-ERCP pancreatitis in all patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of post-ERCP pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the difference in severity of post-ERCP pancreatitis in patients who develop this condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-fine needle aspiration pancreatitis in setting of concomitant ERCP/EUS</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the rates of post-fine needle aspiration (FNA) pancreatitis in the setting of concomitant ERCP/endoscopic ultrasound examinations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1398</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin 100 mg PR x 1 in peri-procedural period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suppositories (#2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>100 mg Indomethacin PR x 1</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled for an ERCP at Dartmouth-Hitchcock

          2. Age greater than 18 years old

          3. Ability to provide written informed consent

        Exclusion Criteria:

          1. Inability to provide written informed consent

          2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis

          3. Current ongoing acute pancreatitis

          4. Previously documented allergy to NSAID

          5. Contra-indication to NSAID therapy (creatinine level &gt;1.4 or active peptic ulcer
             disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)

          6. Pregnant or nursing mothers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Levenick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John M Levenick, MD</last_name>
    <phone>6036508150</phone>
    <email>john.m.levenick@hitchcock.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothy B Gardner, MD</last_name>
    <phone>6036508150</phone>
    <email>timothy.b.gardner@hitchcock.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Levenick, MD</last_name>
      <phone>603-650-8150</phone>
      <email>john.m.levenick@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Timothy B Gardner, MD</last_name>
      <phone>6036508150</phone>
      <email>timothy.b.gardner@hitchcock.org</email>
    </contact_backup>
    <investigator>
      <last_name>John M Levenick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy B Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart R Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>January 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post ERCP acute pancreatitis</keyword>
  <keyword>Post FNA acute pancreatitis</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Rectal NSAIDS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
